(-0.36%) 5 053.61 points
(-0.87%) 38 126 points
(-0.54%) 15 628 points
(1.14%) $83.75
(-2.90%) $1.605
(0.36%) $2 346.80
(0.42%) $27.46
(1.17%) $926.55
(-0.30%) $0.932
(-0.21%) $10.96
(-0.45%) $0.799
(-0.06%) $92.26
Live Chart Being Loaded With Signals
RemeGen Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologics for the treatment of autoimmune, oncology, and ophthalmic diseases with unmet medical needs in Mainland China and the United States...
Stats | |
---|---|
Today's Volume | 1.93M |
Average Volume | 2.67M |
Market Cap | 25.19B |
EPS | HKD0 ( 2023-10-30 ) |
Last Dividend | HKD0 ( N/A ) |
Next Dividend | HKD0 ( N/A ) |
P/E | -9.98 |
ATR14 | HKD0.0660 (0.22%) |
Volume Correlation
REMEGEN-B Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
REMEGEN-B Correlation - Currency/Commodity
REMEGEN-B Financials
Annual | 2023 |
Revenue: | HKD1.08B |
Gross Profit: | HKD825.68M (76.24 %) |
EPS: | HKD-2.80 |
Q4 | 2023 |
Revenue: | HKD313.48M |
Gross Profit: | HKD234.01M (74.65 %) |
EPS: | HKD-0.890 |
Q3 | 2023 |
Revenue: | HKD350.40M |
Gross Profit: | HKD275.25M (78.55 %) |
EPS: | HKD-0.610 |
Q2 | 2023 |
Revenue: | HKD254.19M |
Gross Profit: | HKD175.24M (68.94 %) |
EPS: | HKD-0.700 |
Financial Reports:
No articles found.
REMEGEN-B
RemeGen Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologics for the treatment of autoimmune, oncology, and ophthalmic diseases with unmet medical needs in Mainland China and the United States. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. Its products in various stages of development include RC18, which is under phase III clinical trials for the treatment of neuromyelitis optica spectrum disorder and rheumatoid arthritis, and phase II clinical trials for the treatment of IgA nephritis, Sjögren's syndrome, multiple sclerosis, and myasthenia gravis; RC28, which has completed Phase 1 clinical trials for use in the treatment of wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy; RC98, a PD-L1 monoclonal antibody for the treatment of solid tumors and is under Phase I clinical trial; RC88, which is in Phase 1 clinical trials for use in the treatment of mesothelioma, bile duct carcinoma, pancreatic cancer, ovarian carcinoma, lung adenocarcinoma, and other solid tumors, as well as lung and urothelial cancer; and RC108 that is in Phase 1 clinical trials to treat various solid tumors. In addition, the company's products under pre-clinical development include RC118, RC138, RC148, RC158, RC168, RC178, RC188, and RC198 to treat various solid tumors; and RC208, RC218, and RC228 to treat ophthalmic diseases. RemeGen Co., Ltd. was incorporated in 2008 and is headquartered in Yantai, the People's Republic of China.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators